SteelPeak Wealth’s Harmony Biosciences HRMY Stock Holding History

SteelPeak Wealth’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$583K	Hold	16,000	–	–	0.02%	400
2026 Q1	$448K	Buy	+16,000	New	+$525K	0.01%	393

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SteelPeak Wealth's HRMY Position: Q2 2026 in Review

SteelPeak Wealth held its Harmony Biosciences (HRMY) position steady in Q2 2026 at 16,000 shares worth $583K. The position accounts for 0.02% of the portfolio, ranked #400.

SteelPeak Wealth first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

SteelPeak Wealth held 16,000 shares of Harmony Biosciences worth $583K as of Q2 2026.
SteelPeak Wealth left its Harmony Biosciences share count unchanged in Q2 2026.
Harmony Biosciences made up 0.02% of SteelPeak Wealth's portfolio in Q2 2026, its #400 holding.
SteelPeak Wealth first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on SteelPeak Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.